Third-party tested is not one test: identity, purity, content, sterility and endotoxin

“Third-party tested” sounds precise. It is not. The phrase may refer to one HPLC purity result, a combined identity and purity panel, a content measurement, a microbiological test, or a broader package.

Professional buyers should replace the phrase with a list:

• What sample was tested?
• Which laboratory performed the work?
• Which method and specification applied?
• What result did each test produce?
• Does the evidence cover a submitted sample or the proposed sales batch?

Without those details, two suppliers can both say “third-party tested” while providing materially different evidence.

Five common tests, five different questions

Test area	The question it answers	What it does not establish by itself
Identity	Does the submitted material show analytical evidence consistent with the named peptide?	Purity percentage, amount per vial, sterility, endotoxin level, or batch linkage
Purity	Under the stated chromatographic method, how much of the detected peptide-related material is represented by the main target peak?	Net peptide content, correct fill amount, sterility, or absence of every possible contaminant
Content / amount	How much peptide did the stated quantitative method measure in the submitted unit?	Identity unless identity was tested separately, or sterility and endotoxin control
Sterility	Did the submitted test units meet the stated sterility method and criteria?	Endotoxin absence, chemical identity, purity, or proof that every unit in a batch is sterile
Bacterial endotoxins	What bacterial endotoxin result did the stated method report against its limit?	Sterility, identity, purity, content, or absence of non-endotoxin contaminants

The FDA’s current pyrogen and endotoxins guidance treats bacterial endotoxin testing as its own method and specification question. FDA quality guidance also lists sterility and endotoxins as separate controls for products that purport to be sterile or pyrogen-free. These regulated-product requirements should not be copied blindly onto a research-material COA, but they make the core point clear: one test cannot stand in for another.

Identity: is the submitted material consistent with the named peptide?

Identity work often uses mass spectrometry or another stated analytical technique. The report should show the sample identifier, expected target information, method, and the laboratory’s conclusion.

An identity result does not show how much material is in the vial. It does not establish chromatographic purity, sterility, or endotoxin control. If a report lists purity without a separate identity result, it has answered a narrower question than many buyers assume.

Purity: what does the chromatogram say?

Purity is commonly reported using HPLC or a related chromatographic method. A high area percentage can be useful evidence about the submitted sample under that method.

It is not the same as milligrams per vial. A sample can show a high main-peak percentage while containing less total peptide than the label states. It can also have water, counter-ions, residual solvents, or other material that a headline purity percentage does not explain.

Ask for the method, result, specification, chromatogram or supporting trace where appropriate, and the sample identifier linking the trace to the COA.

Content: how much peptide was measured?

Content, assay, and net peptide quantity are terms that need method-level reading. Record exactly what the laboratory measured, the units, the acceptance range, and whether the result refers to one submitted vial, pooled material, or another sample design.

Do not infer content from purity. 99% purity does not mean 99% of the stated milligrams are present.

For an order decision, compare the content result with the written product specification. Keep the nominal label claim, measured result, method, and acceptance limit as separate fields.

Sterility: a separate microbiological question

A chemical purity report is not a sterility test. If sterility is required by the buyer’s specification or applicable rules, the report needs a named sterility method, sample information, acceptance criterion, and result.

A passing result applies to the submitted test units and stated method. It does not erase the importance of manufacturing controls, container closure, handling, or the sampling plan. Nor does it prove the absence of bacterial endotoxins.

Endotoxin: not the same as sterility

Bacterial endotoxins can remain even when viable bacteria are not detected. Endotoxin testing therefore answers a different question from sterility testing. FDA’s guidance describes gel-clot, photometric, kinetic, and other accepted approaches within an appropriate validated framework; the method must be suitable for the material being tested.

For buyer review, record the method, units, specification limit, measured result, sample identity, and date. Do not translate an endotoxin result into a general statement that a product is “safe,” “clean,” or suitable for a particular use.

Additional panels may matter

Depending on the written specification, buyers may also need to discuss:

• water content;
• counter-ion content;
• residual solvents;
• elemental impurities or heavy metals;
• bioburden;
• particulate matter;
• pH or other product-specific attributes;
• stability under defined storage conditions.

The right panel comes from the product specification, applicable requirements, and the decision being made. It should not be reverse-engineered from whichever tests happen to appear on a supplier’s existing COA.

How to specify a testing package before payment

1. Freeze the product and format. Record product name, stated amount, presentation, packaging, and proposed lot.
2. Name each required panel. Write identity, purity, content, sterility, endotoxin, or other controls separately.
3. Agree the sample stage. State whether the evidence is for a reference sample, pre-production sample, retained sample, or actual proposed batch.
4. Set the evidence scope. Default to Tested Sample unless the tested unit is linked to the proposed lot through recorded identifiers.
5. Confirm the laboratory route. Record where the sample goes, who selects it, who pays, and how the original report will be delivered and verified.
6. Review each result field. A missing panel is not a pass. A conformity footer cannot override a conflicting numerical result.
7. Tie the commercial decision to completed evidence. Use clear gates for pilot approval, larger release, balance payment, and shipment.

The document package around those tests is covered in Peptide documentation package: COA + HPLC + MS + SDS. For report-level reading, see How to read a peptide COA.

Complimentary preliminary review

Request a complimentary preliminary review of one requirement. A complimentary preliminary review is not an approval, clearance, or safe-for-use determination.

WhatsApp: United States +1 303 961 4229 · China +86 180 0545 5057 · Email: sales@batchverity.com

Qualified B2B enquiries only. Laboratory testing and extended investigations are quoted separately.

---

FAQ

Does 99% HPLC purity mean the vial contains the stated amount?

No. Chromatographic purity and peptide content answer different questions. The amount needs a suitable quantitative result reported in the relevant units. For a worked explanation, see why 99% purity does not mean the labeled amount.

Does an identity result prove purity?

No. Identity supports what the submitted material is consistent with. Purity requires its own method and result.

Does a sterility pass mean endotoxin-free?

No. Sterility and bacterial endotoxins are separate tests. Each needs its own method, limit, result, and sample record.

If a COA omits a test, did the sample fail?

Not necessarily. An absent panel usually means the report does not provide that result. Confirm whether it was not ordered, not performed, pending, or not reportable.

What does “full panel tested” mean?

Nothing precise unless the seller lists every panel, method, specification, sample identifier, and result. Ask for the actual test list.

Can one passing vial prove the whole batch?

No. It provides evidence about the submitted material. Documented batch linkage strengthens relevance to the proposed lot, but sampling limits remain.

---

Scope note

This article explains evidence categories for professional B2B review. It is not a laboratory method validation, medical recommendation, legal opinion, or regulatory clearance. Testing requirements and acceptance criteria must be set for the specific material, intended business purpose, destination, and applicable rules.